Ubs Asset Management Americas Inc Atea Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $11,396 - $16,165	2,620 Added 3.0%	90,068 $433,000
Q3 2022 Nov 14, 2022	SELL	$5.49 - $8.79 $77,617 - $124,273	-14,138 Reduced 13.92%	87,448 $497,000
Q2 2022 Aug 12, 2022	BUY	$5.33 - $8.18 $455,379 - $698,874	85,437 Added 529.05%	101,586 $721,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $27,021 - $157,090	3,523 Added 27.9%	16,149 $144,000
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $269,312 - $442,667	12,626 New	12,626 $442,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $281M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.